Navigation Links
Neuralstem Announces 2012 Financial Results, Provides Clinical Trials Update
Date:3/15/2013

icant improvement in both motor and neurological functions in subacute ischemic stroke rats treated with NSI-566 cells seven days post-stroke with increasing intracerebral doses of NSI-566 into the stroke area. A separate research study, "Survival and Differentiation of Human Neural Stem Cells (NSI-566RSC) After Grafting into Ischemia-Injured Porcine Brain," led by Martin Marsala , M.D., professor and the head of the Neuroregeneration Laboratory at University of California, San Diego, demonstrated NSI-566 feasibility and safety in a chronic model of ischemic stroke in mini-pigs, a species that allowed for the use of human-scale transplantation tools and dosing, according to study authors.
  • Subsequent Events:
    In January 2013, Neuralstem received FDA approval to commence a Phase I safety trial of NSI-566 in chronic spinal cord injury (cSCI) patients. The open-label, multi-site study will enroll up to eight patients with thoracic spinal cord injuries (T2-T12), designated American Spinal Injury Association AIS-A level of impairment,  between one and two years after injury. All patients will receive six injections in, or around, the injury site; the first four patients will receive 100,000 cells per injection, and the second four patients will receive 200,000 cells per injection. All patients will also receive physical therapy post-surgery, as well as immunosuppressive therapy, which will be for three months, as tolerated. The trial study period will end six months post-surgery for each patient, with a stated goal of trial completion within a one-year timeframe.
    In February 2013, the company granted licenses to intellectual property surrounding its spinal cord delivery platform, floating cannula, and method for delivering therapeutic agents to the spinal cord to Cedars-Sinai Medical Center, a nonprofit academic medical center located in Los Angeles, CA. The license agreements grant Cedars-Si
    '/>"/>

  • SOURCE Neuralstem, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12

    Related biology technology :

    1. Neuralstem ALS Stem Cell Trial Featured on Fox Atlanta
    2. Neuralstem President and CEO to Update Ongoing ALS and NSI-189/Major Depressive Disorder Trials at 2012 Biotech Showcase
    3. Neuralstem President and CEO to Present at BIO CEO & Investor Conference 2012
    4. Neuralstem Announces Closing of $5.2-Million Registered Direct Offering
    5. Fourteenth Patient Dosed in Neuralstem ALS Stem Cell Trial
    6. Neuralstem CEO to Present at the World Stem Cells and Regenerative Medicine Congress in London
    7. Neuralstem Receives Notice Of Issuance For Patent Covering Human Neural Cell Transplantation For Neurodegenerative Conditions
    8. Neuralstem President And CEO To Present At The 2012 Rodman & Renshaw Annual Healthcare Conference
    9. Neuralstem Cells Induce Significant Functional Improvement In Permanent Rat Spinal Cord Injury, Cell Study Reports
    10. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
    11. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/21/2014)... , Aug. 21, 2014  China Cord Blood Corporation (NYSE: ... plan to release financial results for the first quarter ... after market close in the US.  ... a.m. ET on Friday, August 29, 2014 to discuss ... the Company,s recent developments, followed by a question and ...
    (Date:8/21/2014)... Ontotext S4 , The Self ... . Now the same enterprise hardened text mining, ... unstructured data is available to start-ups and mid-size businesses ... Organizations that do not have resources to evaluate and ... S4 since there is no need for on premise ...
    (Date:8/21/2014)... 2014 On Wednesday of last week RENU ... Redox Signaling molecules, became available for purchase in Australia and ... way that RENU 28 works is, if you think about ... the rate of cellular renewal within your body. If you ... that rate of cellular renewal. What RENU 28 does is ...
    (Date:8/20/2014)... it that American Indians largely were wiped out by ... tuberculosis brought to the New World by European explorers., ... people lived in the Americas shortly before Europeans arrived, ... European diseases., But new research led by anthropological geneticists ... of the University of Tubingen in Germany indicates the ...
    Breaking Biology Technology:China Cord Blood Corporation to Report First Quarter of Fiscal 2015 Financial Results 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 3Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 4RENU 28 Skin Care Now Available in Australia and New Zealand 2Unusual discovery leads to fascinating tuberculosis theory 2Unusual discovery leads to fascinating tuberculosis theory 3
    ... /PRNewswire-Asia-FirstCall/ -- Genesis,Pharmaceuticals Enterprises, Inc. (OTC Bulletin ... pharmaceutical company with its principal operations in ... it engaged KPMG Huazhen,("KPMG"), a member firm ... firms,affiliated with KPMG International, to assist the ...
    ... & Company, LLC, a,Boston-based life science investment bank, ... joined the firm as senior advisor. In ... on internal and client-related activities including,merger & acquisition ... focus on biopharmaceutical transactions. "We are delighted ...
    ... PTNEW YORK, Jan. 13 Keryx Biopharmaceuticals, Inc. (Nasdaq: ... Weiss, the Company,s Chairman and Chief Executive Officer, is ... Healthcare Conference being held in San Francisco.Mr. Weiss, presentation ... 1:00pm PT and will be accessible from the Investor ...
    Cached Biology Technology:Genesis Pharmaceuticals Appoints KPMG to Help Develop a SOX 404 Compliance Program 2Genesis Pharmaceuticals Appoints KPMG to Help Develop a SOX 404 Compliance Program 3Keryx Biopharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference 2
    (Date:8/21/2014)... recently published in the journal Carcinogenesis by ... role for the protein adenomatous polyposis coli (APC) in ... deaths in the U.S. , Lead author Kristi Neufeld, ... co-leader of the Cancer Biology program at the KU ... career trying to understand the various activities of APC, ...
    (Date:8/21/2014)... North Carolina State University have developed a novel and ... has applications for creating new materials as well as ... new technique allows us to model much larger and ... more quickly," says Nan Li, lead author of a ... NC State,s Department of Materials Science and Engineering. "This ...
    (Date:8/20/2014)... Researchers at Huntsman Cancer Institute (HCI) at the University ... the gene that encodes BCR-ABL, the unregulated enzyme driving ... the American Cancer Society, nearly 6,000 new cases of ... in use, called tyrosine kinase inhibitors (TKIs), target BCR-ABL ... not cure CML but control it in a way ...
    Breaking Biology News(10 mins):Research offers insight into cellular biology of colorectal cancer 2Research offers insight into cellular biology of colorectal cancer 3Researchers develop models to study polyelectrolytes, including DNA and RNA 2Blueprint for next generation of chronic myeloid leukemia treatment 2
    ... Infectious diseases can spread very rapidly, so quickly ... However, current testing for such diseases can take hours ... Jayne Wu, associate professor of computer science and electrical ... Eda, associate professor of Forestry, Wildlife and Fisheries at ...
    ... Health, science and medical reporters are invited to register ... Scientific Meeting March 24 at Moscone Center (North), San ... to focus on the results of care-changing investigations that ... options, advance patient care and improve quality of life. ...
    ... The following highlights summarize research papers that have been recently ... Journal of Geophysical Research-Earth Surface ( JGR-F ), ... Journal of Geophysical Research-Solid Earth ( JGR-B ), and ... In this release: , 1. Effect of ...
    Cached Biology News:University of Tennessee researchers invent device to rapidly detect infectious disease 2Media alert: Press registration open for 2012 SIR Annual Scientific Meeting 2AGU Journal highlights - Feb. 29 2012 2AGU Journal highlights - Feb. 29 2012 3AGU Journal highlights - Feb. 29 2012 4AGU Journal highlights - Feb. 29 2012 5AGU Journal highlights - Feb. 29 2012 6AGU Journal highlights - Feb. 29 2012 7AGU Journal highlights - Feb. 29 2012 8AGU Journal highlights - Feb. 29 2012 9
    ... of Agilent analytical solutions is the 6890N ... (LAN) allows you to share business and ... decision making. Just as its 6890 GC ... and performance needed for research and method ...
    ... The 6820 GC system combines world-class ... Chemical QA/QC software, Agilents world-renowned support and ... consumables and supplies--a combination that lets you ... decisions based on dependable data. The Agilent ...
    ... Plus is a small and sensitive ... for both LC and IC. It features ... Pressure Ionization (API) source for outstanding sensitivity ... compatible with existing LC and IC methods, ...
    ... The CHEMICON® CaspaTag™ Caspase-9 Pan-Caspase In ... assay for detection of active caspases in ... research use only. Not for use in ... Situ Caspase Detection Kits use a novel ...
    Biology Products: